These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 14669272

  • 1. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.
    Cancer; 2003 Dec 15; 98(12):2547-53. PubMed ID: 14669272
    [Abstract] [Full Text] [Related]

  • 2. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA, Mamoon N, Mushtaq S, Khadim MT.
    J Coll Physicians Surg Pak; 2009 Feb 15; 19(2):99-103. PubMed ID: 19208313
    [Abstract] [Full Text] [Related]

  • 3. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005 Feb 15; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 4. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M, Nasir A, Aman Z, Ahmad T, Samad A.
    J Ayub Med Coll Abbottabad; 2008 Feb 15; 20(3):23-6. PubMed ID: 19610508
    [Abstract] [Full Text] [Related]

  • 5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 6. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL.
    Cancer; 2003 Apr 15; 97(8):1841-8. PubMed ID: 12673709
    [Abstract] [Full Text] [Related]

  • 7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 8. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.
    Cancer; 2006 Aug 15; 107(4):696-704. PubMed ID: 16826579
    [Abstract] [Full Text] [Related]

  • 9. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D, Middleton LP, Wang S, Valero V, Sahin A.
    Cancer; 2005 Mar 01; 103(5):900-5. PubMed ID: 15643600
    [Abstract] [Full Text] [Related]

  • 10. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun 01; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 11. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K, Bilgi S.
    Exp Oncol; 2005 Jun 01; 27(2):145-9. PubMed ID: 15995634
    [Abstract] [Full Text] [Related]

  • 12. Steroid hormone receptor association with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA, Mamoon N, Mushtaq S, Khadim MT, Jamal S.
    J Coll Physicians Surg Pak; 2010 Mar 01; 20(3):181-5. PubMed ID: 20392381
    [Abstract] [Full Text] [Related]

  • 13. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.
    Cancer; 2003 Mar 15; 97(6):1573-81. PubMed ID: 12627523
    [Abstract] [Full Text] [Related]

  • 14. Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma.
    Zheng W, Zheng J, Ma L, Meng F, Huang L, Ma D.
    APMIS; 2005 Mar 15; 113(3):175-81. PubMed ID: 15799760
    [Abstract] [Full Text] [Related]

  • 15. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M.
    In Vivo; 2007 Mar 15; 21(4):673-8. PubMed ID: 17708365
    [Abstract] [Full Text] [Related]

  • 16. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 May 15; 115(2):349-58. PubMed ID: 18629635
    [Abstract] [Full Text] [Related]

  • 17. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
    Wang SY, Peng DF, Cai ZG, Zhang RZ, Yao TJ, Zhang H, Yang M, Dong HM.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 15; 30(3):203-6. PubMed ID: 18756937
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen value as a marker in breast cancer.
    Narita D, Cimpean AM, Anghel A, Raica M.
    Neoplasma; 2006 Mar 15; 53(2):161-7. PubMed ID: 16575473
    [Abstract] [Full Text] [Related]

  • 19. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.
    Mod Pathol; 2002 Aug 15; 15(8):853-61. PubMed ID: 12181271
    [Abstract] [Full Text] [Related]

  • 20. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.
    J Clin Oncol; 2007 Oct 01; 25(28):4423-30. PubMed ID: 17906205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.